Objectives: To investigate the sensitivity of immunoblotting and enzyme-linked immunosorbent assay (ELISA) to detect autoantibodies to bullous pemphigoid antigen 180 in patients with pemphigoid gestationis and to correlate autoantibody serum levels with disease activity.
Methods: In serum samples obtained from 44 pregnant patients before initiation of therapy and from the same number of healthy blood donors, the autoantibody reactivity was assayed by immunofluorescence microscopy on human skin sections as well as Western blot analysis and 2 different ELISAs by using recombinant forms of the immunodominant domain of BP180. In addition, ELISA reactivity with this autoantigen was assayed in 6 patients during the course of the disease, and its correlation with the clinical disease activity was estimated by applying the Spearman rank correlation test.
Results: By indirect immunofluorescence microscopy, complement-fixing autoantibodies to the dermal-epidermal junction were found in 93% of patients' sera. By immunoblotting and ELISA, autoantibodies to bullous pemphigoid antigen 180 were detected in 93% and 86.3% of pemphigoid gestationis patients, respectively, but in none of the healthy controls. Serum levels of autoantibodies as detected by ELISA paralleled the patients' disease activity.
Conclusions: Our study shows that immunoblotting and ELISA are sensitive tools for the detection of autoantibodies to bullous pemphigoid antigen 180 in patients with pemphigoid gestationis. In addition, the ELISA is useful to monitor autoantibody serum levels.
Level Of Evidence: II-2
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.AOG.0000115506.76104.ad | DOI Listing |
Int J Gynaecol Obstet
December 2024
Department of Obstetrics and Gynecology, Private Clinic, Kocaeli, Turkey.
Objective: To evaluate the maternal and fetal outcomes of 12 pregnant women diagnosed with pemphigoid gestationis, in conjunction with a review of the literature.
Methods: A retrospective review was conducted on the medical records of 12 patients diagnosed with pemphigoid gestationis who presented between January 2014 and January 2024.
Results: Twelve pregnant patients with pemphigoid gestationis were included in the study.
JAAD Case Rep
January 2025
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.
Life (Basel)
November 2024
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Gestational pemphigoid is a rare, autoimmune, subepidermal bullous disease with an incidence of 1 in 50,000 pregnancies, displaying itself through pruritic erythema and urticarial papules and plaques that evolve into tense bullae. Histopathological findings consist of subepidermal vesicles with perivascular eosinophils and lymphocytes, and direct immunofluorescence reveals C3 complement and, more rarely, IgG in a linear band along the basement membrane. The course is usually self-limiting within 6 months after delivery but, later, can be triggered by subsequent pregnancies, menstruation, or treatment with oral contraceptives.
View Article and Find Full Text PDFCureus
October 2024
Internal Medicine and Clinical Immunology Department, Hospital San Juan de Dios, San José, CRI.
Gestational pemphigoid is a rare autoimmune skin condition specific to pregnancy and the postpartum period, with a variable course. There are currently no standardized guidelines referring to evidence-based therapeutic strategies. Intravenous immunoglobulin (IVIG) has recently emerged as a safe and effective steroid-sparing option as a second-line treatment for cases refractory to conventional steroid therapy and for managing relapses.
View Article and Find Full Text PDFCureus
September 2024
Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!